Royal Bank of Canada
ANTX icon

Royal Bank of Canada’s AN2 Therapeutics ANTX Stock Holding History

Royal Bank of Canada’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,812
Closed -$6K – 6810
2024
Q2 		$6K Buy
+2,812
New +$6.69K ﹤0.01% 6474
2023
Q3 		– Sell
-186
Closed -$2K – 7043
2023
Q2 		$2K Sell
186
-456
-71% -$3.28K ﹤0.01% 6838
2023
Q1 		$6K Sell
642
-1,109
-63% -$12.3K ﹤0.01% 6492
2022
Q4 		$17K Buy
1,751
+1,692
+2,868% +$22.7K ﹤0.01% 6361
2022
Q3 		$1K Buy
59
+32
+119% +$373 ﹤0.01% 7138
2022
Q2 		$0 Buy
+27
New +$357 ﹤0.01% 7335

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's ANTX Position: Q3 2024 in Review

Royal Bank of Canada sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 2,812 shares — an estimated $6K sold.

Royal Bank of Canada first reported a position in ANTX in Q2 2022 and held it in 6 quarters. The position peaked at $17K in Q4 2022. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Royal Bank of Canada reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 2,812 AN2 Therapeutics shares in Q3 2024, an estimated $6K.
  • Royal Bank of Canada first reported a position in AN2 Therapeutics in Q2 2022 and held it in 6 quarters.
  • Royal Bank of Canada's AN2 Therapeutics position peaked at $17K in Q4 2022.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Royal Bank of Canada's 13F filing for Q3 2024, filed 14 Nov 2024.